Processa Pharmaceuticals Operating Cycle Over Time

PCSA Stock  USD 2.88  -0.04  -1.37%   
Fundamental trend analysis helps separate temporary noise from persistent changes in Processa Pharmaceuticals.
Pair Processa Pharmaceuticals Performance with Processa Pharmaceuticals Correlation for supplemental context on Processa Pharmaceuticals. This supports a more complete research view.
To understand the process of investing in Processa Stock, visit our How to Invest in Processa Pharmaceuticals guide.As of the week of March 12, Operating Cycle is projected to grow to 669.88.
 Earnings Share
-28.75
 Return On Assets
-1.30
 Return On Equity
-2.71
Investors evaluate Processa Pharmaceuticals using market value and book value, each describing different facets of the business. Processa Pharmaceuticals' market capitalization is 6.53 M. A P/B ratio of 1.12 indicates the market values Processa Pharmaceuticals above its accounting book value. Enterprise value stands at 216.99 K. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Processa Pharmaceuticals are related but not identical, and they can diverge across cycles. For Processa Pharmaceuticals, key inputs include a P/B ratio of 1.12, and ROE of -2.71%. Market price reflects the current exchange level formed by active bids and offers.
Specify up to 10 symbols:

Peer Comparison: Operating Cycle

Compare Processa Pharmaceuticals and related stocks such as Briacell Therapeutics, Curis Inc, and Entero Therapeutics Operating Cycle Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
20102011201220132014201520162017201820192020202120222023202420252026
BCTX0.00.08650.08650.08650.08650.08651.06310.01583.9 K9.7 K9.7 K9.7 K9.7 K9.7 K8.7 K9.2 K
CRIS6.85211.0401-788-878-454-986-1 K113-436118103111107102112129135
PALI2.98392.98392.983933.18184.4 K1.3 K1.4 K522503499216216216216216248236
HOTH0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
MBRX0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
ALLR93.568593.568593.568593.568593.568593.56855.8736130KKKKKKK4.5 K4.8 K
CTXR14.4 K14.4 K14.4 K14.4 K14.4 K14.4 K14.4 K14.4 K14.4 K14.4 K14.4 K14.4 K14.4 K14.4 K38 K34.2 K20.9 K

My Equities

My Current Equities and Potential Positions

Processa Pharmaceuticals
PCSA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Business Address7380 Coca Cola
ExchangeNASDAQ Exchange
USD 2.88

More Resources for Processa Stock Analysis

Reviewing Processa Pharmaceuticals commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Processa Pharmaceuticals' operating context. Outlined below are key reports that provide context for Processa Pharmaceuticals Stock:
Pair Processa Pharmaceuticals Performance with Processa Pharmaceuticals Correlation for supplemental context on Processa Pharmaceuticals. This supports a more complete research view.
To understand the process of investing in Processa Stock, visit our How to Invest in Processa Pharmaceuticals guide.
Analysis related to Processa Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Technical analysis for Processa Pharmaceuticals evaluates price and volume patterns over time. Typical tools include moving averages, relative strength index, regressions, and price correlations.
This view emphasizes price behavior and trend signals over external narrative drivers. This framework highlights recurring patterns and trend context. More Info...